Form 4: AN2 Therapeutics Director Margaret FitzPatrick Granted Stock Options

AN2 Therapeutics, Inc. Director Margaret M. FitzPatrick was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

Summary

• Margaret M. FitzPatrick, a Director of AN2 Therapeutics, Inc. (ANTX), was granted 19,111 stock options on May 22, 2025.
• The stock options have an exercise price of $1.19 per share.
• These options are scheduled to vest on March 31, 2026, contingent upon Ms. FitzPatrick providing continuous service to the company through that date.
• The options have an expiration date of May 21, 2035.
• Following this transaction, Ms. FitzPatrick directly beneficially owns 19,111 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders and is a standard component of compensation packages. It does not indicate any negative operational or financial issues.

Positives

• The grant of 19,111 stock options to Director Margaret M. FitzPatrick aligns her interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a long expiration date of May 21, 2035, providing ample time for potential value realization based on the company's future performance.

Negatives

• N/A

Risks

• N/A

Future Outlook

The stock options granted to Director Margaret M. FitzPatrick are scheduled to vest on March 31, 2026, contingent upon her continuous service to the company.

Management Comments

• N/A

Industry Context

This filing reports an individual insider transaction, which is a routine disclosure for publicly traded companies. Stock option grants are a common form of executive and director compensation across various industries, including biotechnology, used to align the interests of key personnel with those of shareholders.

Comparison to Industry Standards

• N/A

Related Party Transactions

• The grant of stock options to Margaret M. FitzPatrick, a Director of AN2 Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be viewed positively as it aligns the director's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting all employees, such compensation practices reflect a standard approach to incentivizing key personnel and can contribute to overall company stability and growth.

Next Steps

• The stock options are expected to vest on March 31, 2026, assuming continuous service by the reporting person.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, ANTX, Stock Option, Director, Insider Transaction, Form 4, Equity Grant, Compensation